<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308076">
  <stage>Registered</stage>
  <submitdate>17/06/2009</submitdate>
  <approvaldate>1/03/2010</approvaldate>
  <actrnumber>ACTRN12610000181000</actrnumber>
  <trial_identification>
    <studytitle>A randomised double-blind, placebo-controlled trial of magnesium in patients with paroxysmal lone atrial fibrillation.</studytitle>
    <scientifictitle>In patients with paroxysmal lone atrial fibrillation can oral magnesium compared to placebo reduce the incidence of atrial fibrillation?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>paroxysmal lone atrial fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>One oral tablet of Herron Magnesium Plus taken twice daily for 1 year following randomisation.
Herron Magnesium Plus contains:
Magnesium Oxide (Magnesium 320mg) 530.7mg
Manganese sulfate monohydrate (Manganese 5mg) 15.4mg
Pyridoxine hydrochloride (vitamin B6) 50mg</interventions>
    <comparator>One placebo oral tablet taken twice daily for 1 year following randomisation. 
The placebo contains:
Calcium Hydrogen Phosphate 
Pyridoxine Hydrogen Chloride 
Cellulose microcrystalline 
Calcium Stearate 
Water 
Opadry II white 
Iron Oxide black 
Carnauba wax</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of atrial fibrillation confirmed by electrocardiogram or Holter monitor.</outcome>
      <timepoint>1 year following randomisation.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of symptomatic atrial fibrillation detected by the patient, where an ECG was not possible.</outcome>
      <timepoint>1 year following randomisation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with paroxysmal lone atrial fibrillation documented by an electrical tracing (minimum of 2 episodes within prior 12 months)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Renal Failure with a serum urea &gt; 10 mmol/L.
2.Untreated hyperthyroidism.
3.Atrial fibrillation with associated cardiac disease with an abnormal transthoracic echocardiogram; e.g. cardiomyopathy, enlarged left atrium, valvular heart disease. 
4.Symptomatic Inflammatory Bowel disease.
5.Currently taking Magnesium supplementation.
6.Daily consumption of alcohol &gt;4 standard drinks.
7.Transient paroxysmal atrial fibrillation secondary to other reversible disorders (e.g., thyrotoxicosis, cardiac or thoracic surgery, pneumonia, severe anemia)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>An independent researcher will perform computer randomisation of participants  The randomisation lists of ‘active’ and ‘placebo’ status will then be directly emailed to the hospital’s clinical trials pharmacist who will be responsible for all dispensing of study medication throughout the trial.</concealment>
    <sequence>Simple randomisation by using a randomisation table created by computer software (i.e. computerised sequence generation using the statistical software MinitabTrademark(version 15)).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Neuroscience Department, Barwon Health</primarysponsorname>
    <primarysponsoraddress>Ryrie Street
Geelong VIC 3220</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Neuroscience Department, Barwon Health</fundingname>
      <fundingaddress>Ryrie Street
Geelong VIC 3220</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Sigma Pharmaceutical  (Australia) Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress>96 Merrindale Drive, 
Croydon, VIC 3136</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a double-blind, placebo-controlled trial of oral magnesium in patients suffering from paroxysmal atrial fibrillation.  
The aim of this study is to investigate the effect of oral magnesium on the incidence of paroxysmal lone atrial fibrillation. In order to do this participants will be randomised to oral magnesium or placebo. The participants incidence of atrial fibrillation will be monitored for a 12 month period to determine whether oral magnesium reduces the number of episodes of atrial fibrillation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Barwon Health, The Geelong Hospital
Ryrie Street
Geelong VIC 3220</ethicaddress>
      <ethicapprovaldate>18/08/2009</ethicapprovaldate>
      <hrec>09/22</hrec>
      <ethicsubmitdate>14/07/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Peter Gates</name>
      <address>Neuroscience Department
Barwon Health
Ryrie Street
Geelong VIC 3220</address>
      <phone>+61 3 52267950</phone>
      <fax>+61 3 52267375</fax>
      <email>peterga@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Peter Gates</name>
      <address>Neuroscience Department
Barwon Health
Ryrie Street
Geelong VIC 3220</address>
      <phone>+61 3 52267950</phone>
      <fax>+61 3 52267375</fax>
      <email>peterga@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sharon Jones</name>
      <address>Neuroscience Department
Barwon Health
Ryrie Street
Geelong VIC 3220</address>
      <phone>+61 3 52603228</phone>
      <fax>+61 3 52267375</fax>
      <email>sjones@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>